Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₩ 7100
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Oncocross Co., Ltd. engages in conducting joint research on new drugs with several domestic and foreign pharmaceutical companies. It provides a new approach to new drug development by sharing the analysis results using AI new drug development platform. The company was founded by Yi-Rang Kim on June 22, 2015 and is headquartered in Seoul, South...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only
Buy
Sell